The 2023 South China Cardiac Intervention Forum (SCIF 2023) and the South China Intraluminal Imaging and Functionality Summit Forum, as well as the Guangzhou Cardiac Intervention and Heart Failure Forum and the South China Heart Valve Intervention Elite Forum，is jointly organized by the Guangdong Society for Interventional Cardiology, the Guangdong Society for Health Management, the First Affiliated Hospital of Sun Yat sen University and Sun Yat sen Memorial Hospital of Sun Yat sen University. And Co organizing by the China Cardiovascular Imaging and Physiology Elite Club (CCEC), China Cardiovascular Innovation Club (CCI), the Structural Heart Disease Branch of the China Greater Bay Area Heart Association, Guangdong General Hospital, the First People’s Hospital of Foshan, Shenzhen People’s Hospital, and 7th People’s Hospital of Zhengzhou, were held from December 14 to 17, 2023 at the Sofitel Guangzhou Sunrich.
The forum covers various aspects of cardiac intervention, including coronary heart disease intervention, structural heart disease intervention, RND intervention, and more. Based on the combination of theory and practice, renowned domestic and foreign experts and scholars give keynote speeches and share their experiences, from basic theories to the latest developments, from case discussions to surgical broadcasts, to share their experiences and insights on precision intervention therapy. We strive to present a new and rich academic feast for our colleagues.
Ms. Julia Yuan, General Manager of CCRC, was invited to participate in the conference and gave a keynote speech at the Cardiovascular Innovation Forum and CCI Guangzhou Tour: “Key considerations in leveraging China or multi-regional clinical trial for global regulatory approval of medical devices”. CCRC collaborates with top experts, scholars, and industry elites from around the world to explore the technological development, clinical practice, and scientific research innovation in the field of cardiac intervention, shows the professional image of an international leading medical device CRO service leader.
The export of domestic innovative Medicines and medical devices has been an important trend in recent years. One of the key challenges for going abroad comes from strict overseas regulation. For Chinese companies that are not familiar with overseas device regulation and implementation rules, clarifying the differences in global regulatory compliance is extremely challenging.
For Chinese medical device companies that want to sell their products overseas, as well as overseas companies planning to push their products to the Chinese market, breaking down the “information barrier” in the product registration application process and clinical trial implementation standards in various countries is a stubborn stone that must be shattered on the road to going global.
Leveraging China or multi-regional clinical trial for global regulatory approval of medical devices will save product development time and clinical trial costs, deepen understanding of different clinical research and development at home and abroad, cultivate international development experience and talents, and more effectively get closer to the local market. This is very important for domestic medical device enterprises at present.
